TrialNeuro-oncology2009

First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.

Sofiane Maza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.